Janssen Pharmaceutical has asked the U.S. Food and Drug Administration (FDA) to approve the use of intravenous Uptravi (selexipag) by pulmonary arterial hypertension (PAH) patients unable for a given time to use Uptravi as a prescribed oral treatment. The intravenous, or IV (into-the-vein), formulation is meant to prevent treatment interruptions…
News
Letairis (ambrisentan), an approved therapy for pulmonary arterial hypertension (PAH) in adults, appears to also be effective and safe in children ages 8 and older, a study based on clinical trial data reports. All doses tested were well tolerated by children with PAH, and Letairis’ benefit-risk profile was similar to…
Pulmonary hypertension (PH) may be induced by an increased dosage of diazoxide, a therapy used to treat low blood sugar, a case report suggests. The study highlights the need for regular echocardiograms (ECG) during diazoxide treatment to detect PH early. The report, “Pulmonary Hypertension Following Increased…
Rare variants of the ABCC8 gene were found among pulmonary arterial hypertension (PAH) patients in Spain, a study reports. The variants, or mutations, are predicted to alter the SUR1 protein that the ABCC8 gene provides instructions to make, but exactly how these variants might affect PAH remains unknown.
A new virtual tool, called VEST, is aiding clinicians in remotely diagnosing people with Group 1 pulmonary hypertension (PH) per the World Health Organization (WHO) classification, a new study reports. VEST, short for virtual echocardiography screening tool, uses images from routine echocardiography exams of a person’s heart to…
Moderna has entered a collaboration agreement with Chiesi Farmaceutici to develop new messenger RNA-based therapies for pulmonary arterial hypertension (PAH). Messenger RNAs (mRNAs) are the molecules that cells use as a template to make proteins; specifically, mRNAs carry the genetic code from DNA to the protein-making…
The combination of Opsumit (macitentan) and Adcirca (tadalafil) is a safe and effective initial treatment for pulmonary arterial hypertension (PAH), new clinical trial data show. The findings were published in the European Respiratory Journal, in the study, “Initial combination therapy of macitentan and tadalafil…
Delayed diagnosis, limited resources, and a lack of awareness compound barriers to care for people with pulmonary hypertension (PH) in low- and middle-income countries, a recent review found. The finding highlights the need for better patient advocacy across all levels of care, more affordable diagnostic tools, and improved awareness,…
People with intermediate-risk pulmonary arterial hypertension (PAH) who failed to respond adequately to phosphodiesterase-5 inhibitors (PDE5i) show significant benefits when transitioned to Adempas (riociguat) treatment, a Phase 4 trial has found. A total of 41% of patients who made that transition experienced significant clinical improvements, compared with…
Note: This story was updated Sept. 28, 2020, to clarify that Uptravi was being tested as part of an initial triple combination strategy with Opsumit and tadalafil for newly diagnosed patients. An initial triple combination strategy of the oral therapies Uptravi (selexipag), Opsumit (macitentan),…
Using sildenafil and milrinone together proved more effective than either therapy alone in treating newborns with severe persistent pulmonary hypertension (PH), a recent clinical study indicates. This combo treatment may be used in resource-constrained settings that lack inhaled nitric oxide or extracorporeal membrane oxygenation (ECMO) as…
Adults with chronic thromboembolic pulmonary hypertension (CTEPH) experience more breathing stoppages during sleep (apnea), lower blood oxygen, and higher levels of pro-inflammatory proteins in the blood than people with idiopathic pulmonary arterial hypertension who…
